TISIDB

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Note=Associates with centrosomes in interphase and mitosis.
Domain	PF08074 CHDCT2 (NUC038) domain PF08073 CHDNT (NUC034) domain PF00385 Chromo (CHRromatin Organisation MOdifier) domain PF06461 Domain of Unknown Function (DUF1086) PF06465 Domain of Unknown Function (DUF1087) PF00271 Helicase conserved C-terminal domain PF00628 PHD-finger PF00176 SNF2 family N-terminal domain
Function	Component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin by deacetylating histones. Required for anchoring centrosomal pericentrin in both interphase and mitosis, for spindle organization and centrosome integrity.

> Gene Ontology [ TOP ]
Biological Process	GO:0000226 microtubule cytoskeleton organization GO:0006333 chromatin assembly or disassembly GO:0006476 protein deacetylation GO:0007051 spindle organization GO:0016570 histone modification GO:0016575 histone deacetylation GO:0031023 microtubule organizing center organization GO:0032392 DNA geometric change GO:0032508 DNA duplex unwinding GO:0035601 protein deacylation GO:0051297 centrosome organization GO:0071103 DNA conformation change GO:0072331 signal transduction by p53 class mediator GO:0098732 macromolecule deacylation GO:1901796 regulation of signal transduction by p53 class mediator
Molecular Function	GO:0003678 DNA helicase activity GO:0004003 ATP-dependent DNA helicase activity GO:0004386 helicase activity GO:0004407 histone deacetylase activity GO:0008026 ATP-dependent helicase activity GO:0008094 DNA-dependent ATPase activity GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides GO:0016887 ATPase activity GO:0019213 deacetylase activity GO:0033558 protein deacetylase activity GO:0042623 ATPase activity, coupled GO:0070035 purine NTP-dependent helicase activity
Cellular Component	GO:0000118 histone deacetylase complex GO:0005813 centrosome GO:0016581 NuRD complex GO:0017053 transcriptional repressor complex GO:0045111 intermediate filament cytoskeleton GO:0070603 SWI/SNF superfamily-type complex GO:0090545 CHD-type complex GO:0090568 nuclear transcriptional repressor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-427389: ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression R-HSA-212165: Epigenetic regulation of gene expression R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-3214815: HDACs deacetylate histones R-HSA-5250913: Positive epigenetic regulation of rRNA expression R-HSA-73854: RNA Polymerase I Promoter Clearance R-HSA-73864: RNA Polymerase I Transcription R-HSA-73762: RNA Polymerase I Transcription Initiation R-HSA-504046: RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804758: Regulation of TP53 Activity through Acetylation R-HSA-3700989: Transcriptional Regulation by TP53

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-427389: ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-3214815: HDACs deacetylate histones
R-HSA-5250913: Positive epigenetic regulation of rRNA expression
R-HSA-73854: RNA Polymerase I Promoter Clearance
R-HSA-73864: RNA Polymerase I Transcription
R-HSA-73762: RNA Polymerase I Transcription Initiation
R-HSA-504046: RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804758: Regulation of TP53 Activity through Acetylation
R-HSA-3700989: Transcriptional Regulation by TP53

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CHD3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CHD3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CHD3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.133	0.56
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.308	0.87
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.453	0.746
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.035	0.887
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.273	0.928
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.261	0.948
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.27	0.56
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.283	0.885
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.216	0.923
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.002	0.508
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.253	0.581
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.009	0.91

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CHD3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	7.1	17.9	0.405
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	11	3.8	0.73
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	13.6	1.2	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	9.1	6.3	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	33.3	0	33.3	0.0365
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	0	40	0.11
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	7.4	0.5	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	14.3	-1.8	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CHD3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CHD3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CHD3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CHD3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CHD3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CHD3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CHD3
Name	chromodomain helicase DNA binding protein 3
Aliases	Mi-2a; ZFH; Mi2-ALPHA; ATP-dependent helicase CHD3; CHD-3; hZFH; mi-2 autoantigen 240 kDa protein; zinc-fing ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CHD3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CHD3